Frank A. Alleva is a Managing Director at Blue Owl and member of the Tax Team. In his role, he is primarily focused on product structuring, tax compliance, investor reporting and other asset management tax operational matters across the various business strategies.

Before joining Blue Owl, Frank was a Vice President at Blackstone focused on both the publicly traded company and head of retail funds tax. Prior to that, he was a Tax Manager at PwC in the Real Estate Asset Management practice. Frank began his career at KPMG in the Real Estate and Construction Tax practice.
 
Frank received a BS in Accounting and a MS in Taxation from St. John’s University, where he graduated magna cum laude. Frank is a licensed Certified Public Accountant in New York.

Haitham Abdulkarim is a Managing Director at Blue Owl and member of the Institutional Business Development Team. In his role, he focuses on capital raising and fund formation in the Middle East, working closely with a variety of internal stakeholders to bring the firm’s investment strategies to the region.

Before joining Blue Owl, Haitham was a senior member of the Middle East Institutional Client Business team at BlackRock; leading client strategy and engagement for the United Arab Emirates, Oman, and Bahrain. Haitham was previously responsible for promoting BlackRock’s private markets offering to investors in the Kingdom of Saudi Arabia, and helped establish the firm's first fund dedicated to the region. Prior to that, he led investor relations at Mubadala-backed Waha Capital in Abu Dhabi and at Samena Capital, a pan-Asia private equity firm based out of Dubai. Haitham began his career in Mergers & Acquisitions, with roles at HSBC Global Banking & Markets and BNP Paribas CIB in Dubai and Singapore.

He received his Bachelor of Arts (Honors) in Finance, Accounting & Management from the University of Nottingham in the United Kingdom.

Sandip Agarwala is a Managing Director at Blue Owl and member of the Direct Lending Investment Team. In his role, he focuses on life sciences credit, royalty and growth equity investments.

Before joining Blue Owl, Sandip was a Managing Director at Longitude Capital, a life sciences focused investment firm. Prior to that, he was a Vice President at Auven Therapeutics Management. Sandip began his career as a management consultant with The Boston Consulting Group and The Frankel Group.

Sandip received his MBA in Finance and Healthcare Management from The Wharton School of the University of Pennsylvania and holds a BSE in Systems Science and Engineering from the University of Pennsylvania.

Ilan Aharoni is a Principal at Blue Owl and member of the Direct Lending Investment Team. In his role, he is focused on growth-stage investing in leading technology businesses, primarily across SaaS, Infrastructure, and Security.

Before joining Blue Owl, Ilan was a Senior Associate at Vector Capital, a technology-focused private equity fund based in San Francisco. Ilan began his career as an Investment Banking Analyst at J.P. Morgan in London and San Francisco.

Ilan received a BS in International Business Administration and an MS in Finance and Investments, cum laude, from Rotterdam School of Management – Erasmus University in the Netherlands.

David Aidi is a Managing Director at Blue Owl and member of the Alternative Credit Investment Team. In his role as co-head of the Financial Assets team within Alternative Credit, he is jointly responsible for the team's efforts in specialty finance.

Before joining Blue Owl, David was a Partner at Atalaya Capital Management, the predecessor firm to Blue Owl's Alternative Credit team, where he co-founded the Financial Assets team and co-led the firm's efforts in specialty finance. At Atalaya, David sat on the firm’s Executive Committee, multiple Investment Committees, and led the firm’s Asset Income Fund investment strategy. Prior to joining Atalaya, David was the Portfolio Manager in charge of the Direct Lending Group and a member of the firm-wide Investment Committee at Magnetar Capital, where he oversaw a portfolio of public and private credit investments. Previously, he was an analyst at Highbridge/Zwirn Capital Management, focused on private credit and other special situation investments. David began his career at Merrill Lynch, holding positions within the High Yield Capital Markets Group as well as the Telecommunications, Media and Technology Investment Banking Group.

David holds a BS in Business Administration, summa cum laude, from the Stern School of Business at New York University where he majored in Finance and Economics.

Michael Allegretto is a Principal at Blue Owl and member of the Information Technology Team. In his role, he is responsible for the technology and security aspects of the firm's Governance, Risk, and Compliance (GRC) framework. He partners closely with Legal, Compliance, and other stakeholders to ensure Blue Owl's technology operations align with its regulatory, risk management, and strategic objectives.

Before joining Blue Owl, Michael was the Head of Infrastructure and Security at Atalaya Capital Management, the predecessor firm to Blue Owl's Alternative Credit team. Prior to that, he was the Head of Technology at Bridgewater China.

Michael received his BBA in Management Information Systems from Western Connecticut State University.

Joe Alongi is a Managing Director at Blue Owl and the Chief Financial Officer, Private Credit Funds. Joe is a member of the firm's Operating Committee as well as the Blue Owl Credit Operating and Valuation Committees.

Prior to joining Blue Owl in 2018, Joe was a Director at Guggenheim Partners Investment Management, where he served as a Controller in the Private Commingled Fund Accounting Group and was responsible for the accounting and reporting for various Alternative Investment Funds and CLOs. Prior to that, Joe worked within the Financial Services practice of PwC where he specialized in audits of alternative investment funds and registered investment companies.

Joe received a BS in Accounting from Villanova University and is a licensed Certified Public Accountant in New York.

Kaitlin Alvarez is a Principal at Blue Owl and member of the Investor Operations Team. Based in Short Hills, she focuses on strategic projects and technology initiatives.

Before joining Blue Owl, Kaitlin was the Senior Manager of Investor Services at Warburg Pincus, a private equity firm based in New York, where she identified enhancements to procedures to improve efficiency and reduce risk. 

Kaitlin received both her MA and BA in Communication from Marist College.

Kerri Amato is a Managing Director at Blue Owl and member of the Compliance Team. Kerri serves as both the Chief Compliance Officer of Blue Owl Securities LLC, the firm’s limited purpose broker-dealer and as the Head of Compliance Distribution, where she focuses on supporting Blue Owl’s global expansion.

Before joining Blue Owl, Kerri was a Managing Director at AQR Capital Management, LLC and served as the Chief Compliance Officer for AQR Investments, LLC. Kerri began her career as a Marketing Associate then transitioned to the Compliance Team at Arhnold & S. Bleichroeder Advisers LLC.

Kerri received her BBA in International Finance and Marketing from the University of Miami and holds a MBA in Finance and Marketing from Baruch College, Zicklin School of Business.

Timothy Anderson is a Managing Director at Blue Owl and member of the Healthcare Opportunities Investment Team. In his role, he focuses on investments in biotechnology, diagnostics, and digital medicine companies and sits on the Fund's Investment Committee.

Previously Tim was a co-founding member and Managing Director of Cowen Healthcare Investments, the predecessor to Blue Owl Healthcare Opportunities. Prior to his role at Cowen Healthcare Investments, Tim was a biotechnology investment banker at Cowen and Company.

He is currently a member of the Board of Directors of Lycia Therapeutics, F2G, Anaveon, Autobahn Therapeutics and Scipher Medicine. Tim previously served as a Board Member or Board Observer of Tourmaline Bio, Vectiv Bio Holdings, Therachon, Precision Biosciences, Livongo Health, Cadent Therapeutics, Cullinan Oncology and Compass Therapeutics. Tim received a BA in both Economics and Government & Legal studies from Bowdoin College.